Gibson Assembly Cloning Method

| September 30, 2018

article image
The Gibson Assembly® method has quickly become an invaluable tool for molecular cloning workflows due to its flexibility and efficiency. It allows for the cloning of multiple fragments directly into any vector without the use of restriction enzymes. Gibson Assembly Primer-Bridge End Joining (PBnJTM) allows a single primer or primer pair with phosphorothioate-modified bases to bridge together the ends of DNA fragments.

Spotlight

Crescent Pharma Ltd

Crescent Pharma Limited is an established UK registered pharmaceutical company with a wide range of experience in the development, quality control and marketing of generic medicinal products.

OTHER ARTICLES

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 26, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 26, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 26, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Spotlight

Crescent Pharma Ltd

Crescent Pharma Limited is an established UK registered pharmaceutical company with a wide range of experience in the development, quality control and marketing of generic medicinal products.

Events